CLAIMS

1. Use of tolerizing immune modifying particles encapsulating peanut proteins (TIMP-PPE), alone or in combination with one or more therapeutics in the preparation of a medicament for treating peanut allergy in a subject, wherein TIMP-PPE is to be administered at a dose level of between about 0.001 mg/kg and 12 mg/kg.

2. The use of claim 1, wherein the TIMP-PPE particles have an average diameter of between 100 nm and 1500 nm.

3. The use of claim 1 or 2, wherein the TIMP-PPE particles have a negative zeta potential, optionally wherein the particles have a negative zeta potential of between -30 mV and -100 mV.

4. The use of any one of the preceding claims, wherein TIMP-PPE is to be administered at a concentration of between about 0.0005 mg/mL and about 50 mg/mL, optionally about 0.0005 mg/mL, 0.001 mg/mL, 0.005 mg/mL, 0.01 mg/mL, 0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL, 1 mg/mL, 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, 11 mg/mL, 12.5 mg/mL, 15 mg/mL, 17.5 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL, 40 mg/mL, or 50 mg/mL.

5. The use of any one of the preceding claims, wherein TIMP-PPE is to be administered at a dose level of about 0.001 mg/kg, 0.0025 mg/kg, 0.005 mg/kg, 0.01 mg/kg, 0.025 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 4.0 mg/kg, 6 mg/kg, 8.0 mg/kg, 10 mg/kg, or 12 mg/kg or wherein TIMP-PPE is to be administered at a dose level of between about 0.1 mg and 800 mg.

6. The use of any one of the preceding claims, wherein TIMP-PPE is to be administered once weekly, once every two weeks, once every three weeks, once every 4 weeks, once every two months, once every three months, once every 6 months, or once per year or wherein TIMP-PPE is to be administered in two doses one-week apart..

7. The use of any one of the preceding claims, wherein TIMP-PPE is to be administered intravenously, subcutaneously, intramuscularly, intraperitoneally, intranasally, or orally.

8. The use of any one of the preceding claims wherein TIMP-PPE is to be administered in two doses one-week apart followed by a booster dose of TIMP-PPE re-administered as a single dose once every three months.

9. The use of any one of claims 1-8, wherein the therapeutic to be administered in combination with TIMP-PPE is an anti-IgE antibody, anti-IL-4Rα antibody, anti-IL13 antibody, an anti-IL-33 antibody, an antihistamine, a steroid, a corticosteroid, a leukotriene modifier, low dose IL-2, IL-2 muteins engineered to expand Tregs, IL-2 variants engineered to expand Tregs, IL-2 molecules engineered to be selective for the high-affinity IL-2 receptor, PEGylated IL-2, IL-2 complexes, IL-2/CD25 fusion proteins, a prebiotic, a probiotic, histone deacetylase inhibitor, short chain fatty acids (e.g. acetate, butyrate, propionate, butyrate polymer), an inhibitor of IgE, competitor of IgE for allergen binding sites, an inhibitor of basophil activation, an inhibitor of mast cell activation, a cytokine inhibitor, microbiome therapy, a small molecule or biological therapeutic, or a nonsteroid anti-inflammatory drug (NSAID).

10. The use of any one of the preceding claims, wherein the administration of TIMP-PPE alone or in combination with an additional therapeutic to the subject is for reducing one or more symptoms of peanut allergy, optionally wherein the one or more symptoms of peanut allergy are selected from the group consisting of skin reactions, hives, skin redness, skin swelling, itching, tightening of the throat, difficulty breathing, shortness of breath, digestive problems such as diarrhea, stomach cramps, nausea, vomiting, drop in blood pressure and anaphylaxis.

11. The use of any one of the preceding claims, wherein the administration of TIMP-PPE alone or in combination with a therapeutic to the subject is for increasing tolerance to peanut proteins.

12. The use of any one of the preceding claims, wherein the TIMP-PPE comprises a peanut extract or one or more peanut proteins or antigenic fragments thereof selected from the group consisting of Ara h1, Ara h2, Ara h3, Ara h5, Ara h6, Ara h7, Ara h8, Ara h9, Ara h10, Ara h11, Ara h12, Ara h13, Ara h14, Ara h15, Ara h16, Ara h17, and Ara h18.

13. The use of any one of the preceding claims, wherein the TIMP-PPE comprises one or more proteins or antigenic fragments thereof of Ara h1, Ara h2, Ara h3, Ara h5, Ara h6, Ara h7, or Ara h8 or combinations thereof.

14. The use of any one of the preceding claims, wherein the subject is to be administered an antihistamine, a corticosteroid, a NSAID and/or a leukotriene modifier in combination with TIMP-PPE.